Please assess the completion status of the following clinical trial:

Trial Title: Inflammation After One Lung Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20-70 years~* American Society of Anaesthesiologists (ASA) physical status I-III~* elective open lobectomy with OLV~Exclusion Criteria:~* history of drug hypersensitivity~* drug addiction~* treatment with psychotropic drugs~* severe psychiatric and central nerve system diseases~* persistent tobacco abuse, autoimmune system diseases~* diabetes mellitus~* cardiac failure (New York Heart Association class greater than 2)~* clinically relevant obstructive and restrictive lung diseases (vital capacity or forced expiratory volume in 1s lover than 50% of the predicted values)~* pulmonary hypertension (mean pulmonary arterial pressure grater than 25 mmHg)~* pre-existing coagulation disorders~* history of treatment with immunosuppressant drugs in the 4 weeks before surgery~* Patient with evidence of pulmonary or systemic infections (C-reactive protein serum concentration greater than 5 mg/L, leucocytosis greater than 10.0 bioparticles/L or body temperature greater than 37 stC)~* perioperative blood derivatives, steroids or non-steroidal anti-inflammatory drug (NSAID)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: EXPERIMENTAL): Sevoflurane group (S group)- The group anaesthesied with sevoflurane
- Propofol (Type: ACTIVE_COMPARATOR): Propofol 4-6 mg/kg/h iv

Based on this trial design, predict the completion outcome and termination type (if applicable).